Dr. Keith Flaherty

Dr. Keith Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School. As described in the more than 300 peer reviewed primary research reports he has authored or co-authored, Dr. Flaherty and colleagues made several seminal observations that have defined the treatment of melanoma when they established the efficacy of BRAF, MEK and combined BRAF/MEK inhibition in patients with metastatic melanoma in a series of New England Journal of Medicine articles for which Dr. Flaherty was the first author. He is the principal investigator of the NCI MATCH trial, the first NCI-sponsored trial assigning patients to targeted therapy independent of tumor type on the basis of DNA sequencing detection of oncogenes. He serves ECOG as chair of the Developmental Therapeutics Committee and in 2013 was appointed as ECOG Deputy Chair for Biomarker Science. Dr. Flaherty joined the NCI Board of Scientific Advisors in 2018 and AACR Board of Directors in 2019. He serves as editor-in-chief of Clinical Cancer Research.